<SEC-DOCUMENT>0001567619-23-005526.txt : 20230405
<SEC-HEADER>0001567619-23-005526.hdr.sgml : 20230405
<ACCEPTANCE-DATETIME>20230405212806
ACCESSION NUMBER:		0001567619-23-005526
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230324
FILED AS OF DATE:		20230405
DATE AS OF CHANGE:		20230405

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Kim Robert Young
		CENTRAL INDEX KEY:			0001971608

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39782
		FILM NUMBER:		23804228

	MAIL ADDRESS:	
		STREET 1:		C/O 4D MOLECULAR THERAPEUTICS, INC.
		STREET 2:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			4D Molecular Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001650648
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				473506994
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5105052680

	MAIL ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	4D Molecular Therapeutics Inc.
		DATE OF NAME CHANGE:	20200506

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	4D Molecular Therapeutics Inc
		DATE OF NAME CHANGE:	20150811
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc1.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2023-03-24</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001650648</issuerCik>
        <issuerName>4D Molecular Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>FDMT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001971608</rptOwnerCik>
            <rptOwnerName>Kim Robert Young</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O 4D MOLECULAR THERAPEUTICS INC.</rptOwnerStreet1>
            <rptOwnerStreet2>5858 HORTON STREET #455</rptOwnerStreet2>
            <rptOwnerCity>EMERYVILLE</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94608</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Medical Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Options (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>18.66</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2030-11-08</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>150000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Options (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>15.78</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-01-31</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>70000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Options (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.04</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-08-31</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>60000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Options (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>20.24</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-02-09</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>40000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">25% of the shares subject to the option vest on the first anniversary measured from October 7, 2020 (the &quot;Vesting Commencement Date&quot;), and 1/48th of the total number of shares vest and become exerciseable in equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.</footnote>
        <footnote id="F2">The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the &quot;Vesting Commencement Date&quot;) such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.</footnote>
        <footnote id="F3">The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the &quot;Vesting Commencement Date&quot;) such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.</footnote>
        <footnote id="F4">The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the &quot;Vesting Commencement Date&quot;) such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ August J. Moretti, Attorney-in-Fact for Robert Kim</signatureName>
        <signatureDate>2023-04-05</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>robertkimmdpoa.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 170.95pt; margin-left: 170.1pt; margin-top: 4.3pt; font-weight: bold;">POWER OF ATTORNEY</div>
    <div style="margin-top: 0.45pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 35.95pt; margin-right: 5.6pt; margin-left: 5pt; margin-top: 0.05pt;">KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and
      appoints each of (i) the Chief Executive Officer of 4D Molecular Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;),
      who is currently David Kirn, (ii) the Company&#8217;s Chief Financial Officer, who is currently August J. Moretti, and (iii) the Company&#8217;s Chief Legal and Human Resources Officer, who is currently Scott Bizily, and their respective successors, signing
      singly, with full power of substitution, as the undersigned&#8217;s true and lawful attorney-in-fact to:</div>
    <div style="margin-top: 0.55pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z333ffa7cc1b941a5a5b7131c8a94a75b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 41pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>execute for and on behalf of the undersigned, in the undersigned&#8217;s capacity as an officer and/or director of the Company, Forms 3, 4 and 5 (including amendments
              thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;</div>
          </td>
        </tr>

    </table>
    <div style="margin-top: 0.5pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7ff92039b0f34156aa2af7b476858b0e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 41pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4 or 5 or Form ID and
              timely file such forms (including amendments thereto) and application with the United States Securities and Exchange Commission and any stock exchange or similar authority; and</div>
          </td>
        </tr>

    </table>
    <div style="margin-top: 0.5pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1b6846ff50af4e0f87313831f3d4b10a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 41pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">(3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest
              of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and
              conditions as such attorney-in-fact may approve in such attorney-in- fact's discretion.</div>
          </td>
        </tr>

    </table>
    <div style="margin-top: 0.55pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 35.95pt; margin-right: 5.75pt; margin-left: 5pt;">The undersigned hereby grants to each such attorney-in-fact full power and authority to do
      and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally
      present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney
      and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's
      responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.</div>
    <div style="margin-top: 0.4pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 35.95pt; margin-right: 5.6pt; margin-left: 5pt; margin-top: 0.05pt;">The undersigned agrees that each such attorney-in-fact herein may rely
      entirely on information furnished orally or in writing by the undersigned to such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or
      liabilities (or actions in these respects) that arise out of or are based upon any untrue statements or omission of necessary facts in the information provided by the undersigned to such attorney-in fact for purposes of executing, acknowledging,
      delivering or filing Forms 3, 4 or 5 (including amendments thereto) or Form ID and agrees to reimburse the Company and such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any
      such loss, claim, damage, liability or action.</div>
    <div style="text-align: justify; text-indent: 35.95pt; margin-right: 5.7pt; margin-left: 5pt; margin-top: 4.05pt;">This Power of Attorney supersedes any power of attorney previously
      executed by the undersigned regarding the purposes outlined in the first paragraph hereof ("<font style="font-weight: bold; font-style: italic;">Prior Powers of Attorney</font>"), and the
      authority of the attorneys-in-fact named in any Prior Powers of Attorney is hereby revoked.</div>
    <div style="margin-top: 0.5pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 35.95pt; margin-right: 5.75pt; margin-left: 5pt;">This Power of Attorney shall remain in full force and effect until the undersigned is no
      longer required to file Forms 3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier (a) revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact
      or (b) superseded by a new power of attorney regarding the purposes outlined in the first paragraph hereof dated as of a later date.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 35.95pt; margin-right: 5.75pt; margin-left: 5pt;">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of
      this 24th day of March 2023.</div>
    <div style="margin-top: 0.5pt;"><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="margin-top: 0.15pt;"><br>
    </div>
    <div style="margin-right: 87.5pt; margin-left: 176.2pt;"><u>/s/ Robert Kim</u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="margin-right: 130.75pt; margin-left: 176.2pt; font-variant: small-caps; font-weight: bold;">Robert Kim, M.D.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="margin-top: 4.55pt;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
